This 2011 narrative review synthesizes evidence on proinflammatory cytokines as central drivers of OA pathophysiology. It focuses on IL-1β, TNF, and IL-6 as the primary mediators of cartilage destruction, synovial inflammation, and subchondral bone remodeling. It also evaluates the translational potential of anticytokine therapies based on preclinical and early clinical trial data.
OA was long taught as a purely mechanical wear-and-tear disease, but this review consolidates the evidence that it is sustained by a self-amplifying cytokine network operating from the earliest disease stages.
When counseling patients on why NSAIDs and corticosteroids provide only symptomatic relief, this framework explains it: neither targets the upstream IL-1β/TNF/NF-κB axis driving ongoing matrix destruction.
When interpreting biologic trial results for OA, keep the anakinra story in mind. A failed RCT does not necessarily mean the wrong target. Short intra-articular drug half-life and patient selection (low baseline pain) are real design confounders that must be addressed in future trials.
The ADAMTS-4 vs. ADAMTS-5 distinction matters clinically: mouse knockout data initially implicated ADAMTS-5 as the dominant aggrecanase, but cytokine-stimulation studies in human and large-animal tissue show ADAMTS-4 is the relevant target in cytokine-driven human OA — a reminder that murine models do not always translate directly.
This 2011 narrative review synthesizes evidence on proinflammatory cytokines as central drivers of OA pathophysiology. It focuses on IL-1β, TNF, and IL-6 as the primary mediators of cartilage destruction, synovial inflammation, and subchondral bone remodeling. It also evaluates the translational potential of anticytokine therapies based on preclinical and early clinical trial data.
OA was long taught as a purely mechanical wear-and-tear disease, but this review consolidates the evidence that it is sustained by a self-amplifying cytokine network operating from the earliest disease stages.
When counseling patients on why NSAIDs and corticosteroids provide only symptomatic relief, this framework explains it: neither targets the upstream IL-1β/TNF/NF-κB axis driving ongoing matrix destruction.
When interpreting biologic trial results for OA, keep the anakinra story in mind. A failed RCT does not necessarily mean the wrong target. Short intra-articular drug half-life and patient selection (low baseline pain) are real design confounders that must be addressed in future trials.
The ADAMTS-4 vs. ADAMTS-5 distinction matters clinically: mouse knockout data initially implicated ADAMTS-5 as the dominant aggrecanase, but cytokine-stimulation studies in human and large-animal tissue show ADAMTS-4 is the relevant target in cytokine-driven human OA — a reminder that murine models do not always translate directly.